A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.
Animals
Atherosclerosis
/ drug therapy
CD36 Antigens
/ metabolism
Diabetes Mellitus, Type 1
/ drug therapy
Diabetes Mellitus, Type 2
/ metabolism
Dipeptidyl-Peptidase IV Inhibitors
/ pharmacology
Foam Cells
/ drug effects
Glycation End Products, Advanced
/ metabolism
Humans
Macrophages, Peritoneal
/ drug effects
Male
Mice
Mice, Inbred C57BL
Pyrazoles
/ pharmacology
Sterol O-Acyltransferase
/ metabolism
THP-1 Cells
/ drug effects
Thiazolidines
/ pharmacology
ACAT-1
AGEs
CD36
DPP-4 inhibitors
macrophage foam cell formation
type 1 diabetes
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Jul 2020
07 Jul 2020
Historique:
received:
11
05
2020
revised:
27
06
2020
accepted:
06
07
2020
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
18
2
2021
Statut:
epublish
Résumé
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to play a protective role against atherosclerosis in both animal models and patients with type 2 diabetes (T2D). However, since T2D is associated with dyslipidemia, hypertension and insulin resistance, part of which are ameliorated by DPP-4 inhibitors, it remains unclear whether DPP-4 inhibitors could have anti-atherosclerotic properties directly by attenuating the harmful effects of hyperglycemia. Therefore, we examined whether a DPP-4 inhibitor, teneligliptin, could suppress oxidized low-density lipoprotein (ox-LDL) uptake, foam cell formation,
Identifiants
pubmed: 32646003
pii: ijms21134811
doi: 10.3390/ijms21134811
pmc: PMC7369823
pii:
doi:
Substances chimiques
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
0
CD36 Antigens
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glycation End Products, Advanced
0
Pyrazoles
0
Thiazolidines
0
Sterol O-Acyltransferase
EC 2.3.1.26
sterol O-acyltransferase 1
EC 2.3.1.26
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Pharmacol Drug Dev. 2013 Jul;2(3):246-54
pubmed: 27121786
Diabetes Care. 2015 Jan;38(1):119-25
pubmed: 25336748
Diabetes. 2015 Jan;64(1):257-65
pubmed: 24848072
Mol Med. 1999 Jun;5(6):393-405
pubmed: 10415164
Horm Metab Res. 2012 Jun;44(7):501-5
pubmed: 22581648
Microvasc Res. 2018 Nov;120:90-93
pubmed: 30056058
Am J Hypertens. 2019 Jun 11;32(7):695-702
pubmed: 31045223
J Am Geriatr Soc. 2009 Oct;57(10):1874-80
pubmed: 19682127
J Cardiovasc Pharmacol. 2011 Aug;58(2):157-66
pubmed: 21558879
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Pharmacol Res. 2011 May;63(5):383-8
pubmed: 21320599
Diabetes Care. 2016 Jan;39(1):139-48
pubmed: 26628419
Int J Endocrinol. 2018 Dec 9;2018:8458304
pubmed: 30627161
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
Infect Immun. 1999 Nov;67(11):5573-8
pubmed: 10531202
Lab Invest. 2015 May;95(5):525-33
pubmed: 25730373
Circulation. 2006 Aug 8;114(6):597-605
pubmed: 16894049
Atherosclerosis. 2009 Aug;205(2):590-4
pubmed: 19185865
Diabetologia. 2011 Oct;54(10):2649-59
pubmed: 21786155
PLoS One. 2013 Aug 13;8(8):e70933
pubmed: 23967137
Metabolism. 2012 Jul;61(7):974-7
pubmed: 22225957
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Acta Diabetol. 2016 Jun;53(3):461-8
pubmed: 26687195
Am J Pathol. 1995 Sep;147(3):654-67
pubmed: 7545874
J Biol Chem. 2006 Jul 21;281(29):20213-20
pubmed: 16707486
Diabetes Metab Res Rev. 2018 Nov;34(8):e3059
pubmed: 30098301
Cell. 2001 Feb 23;104(4):503-16
pubmed: 11239408
Cardiovasc Diabetol. 2015 Jan 13;14:2
pubmed: 25582643
Mol Med. 2015 Oct 27;21 Suppl 1:S32-40
pubmed: 26605646
Diabetes Metab Res Rev. 2013 Nov;29(8):624-30
pubmed: 23861159
Nature. 2000 Sep 14;407(6801):233-41
pubmed: 11001066
Diabetologia. 2019 Feb;62(2):269-280
pubmed: 30460578
JAMA. 2019 Jan 1;321(1):69-79
pubmed: 30418475
Int J Cardiol. 2015 Apr 1;184:14-6
pubmed: 25705004
Eur Heart J. 2014 May;35(17):1137-46
pubmed: 24126878
Diabetes Res Clin Pract. 2019 Dec;158:107904
pubmed: 31672500
Cardiovasc Diabetol. 2013 Aug 28;12:125
pubmed: 23984879
Diabetes Care. 2011 Feb;34(2):442-7
pubmed: 21270199
Diabetes Metab Res Rev. 2011 Sep;27(6):557-63
pubmed: 21538775
Curr Pharm Des. 2011 Dec;17(38):4379-85
pubmed: 22204436
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
BMC Pharmacol Toxicol. 2020 Apr 21;21(1):28
pubmed: 32317005
PLoS One. 2012;7(4):e35683
pubmed: 22536426
Horm Metab Res. 2011 Sep;43(10):731-4
pubmed: 21932180
Diabetes Care. 2016 Mar;39(3):455-64
pubmed: 26822324
Circ Res. 2004 Apr 16;94(7):892-901
pubmed: 15001526
Acta Diabetol. 2014;51(3):471-8
pubmed: 24363097
Lipids Health Dis. 2016 Sep 19;15(1):161
pubmed: 27644038
Aging Clin Exp Res. 2009 Apr;21(2):182-90
pubmed: 19448391
Cardiovasc Res. 2012 Jul 15;95(2):165-72
pubmed: 22345306
Circ J. 2019 Aug 23;83(9):1822-1828
pubmed: 31366777
J Biol Chem. 2005 Feb 4;280(5):3355-64
pubmed: 15556945
Diabetes Care. 2012 Dec;35(12):2618-25
pubmed: 22912424
Diabetologia. 2007 Jul;50(7):1409-17
pubmed: 17479244